Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies

20260 citationsJournal Articlegold Open Access

Authors

J. Zhu · Peking University

J. Li · Jiangsu Province Hospital

C.S. Tam · Monash University

L. Wang · Beijing Enterprises (China)

J. Xu · Universidad San Carlos

J. Zhang · Universidad San Carlos

P. Khanna · AMS (Singapore)

Abstract

Zanubrutinib was well tolerated in Asian patients with B-cell malignancies. The safety profile in this population was consistent with that in previous global study populations. These findings suggest that long-term zanubrutinib treatment is an appropriate option for Asian patients with B-cell malignancies.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 11, Issue 4, pp. 106086-106086

DOI: 10.1016/j.esmoop.2026.106086

Field-Weighted Citation Impact: 0.00